Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Visit the company website

 

Bullboard - Investor Discussion Forum Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX... see more

TSXV:VM - Post Discussion

View:
Post by WarrantOfficer on Jan 17, 2025 6:55am

LOI Timeline

This video released yesterday, Brent states 60 - 90 days for LOI finalization.


(88) Voyageur Pharmaceuticals CEO recaps milestone achievements in 2024 and outlines goals for 2025 - YouTube
Comment by JrOGInvestor on Jan 17, 2025 7:17am
Yup, saw it. That paved road from Anchorage is almost complete. I wouldn't be surprised if they were waiting for a higher share price, It's what they are exchanging for cash, that and a percentage of the barium/iodine vault. If the sp is higher it costs them less materials. 
Comment by postie1 on Jan 17, 2025 9:57am
Seen an interesting post over on the CEO
Comment by lscfa on Jan 17, 2025 5:39pm
So you think Bayer Ag is the interested pharma? It would make sense as it appears they do not make barium contrast products, Only iodine-based and gadolinium-based.
Comment by postie1 on Jan 17, 2025 7:28pm
I do not know but it is interesting who liked it. I am of my own opinion and this just my own opinion that the company that ties VM up will eventually take it out if we actually get future products from them. IMO opinion I do not think a major is going to collabrate just for the fun of it. With the clout of any major behind VM I would think ( imo and only my opinion) the percentage of market share ...more  
Comment by JrOGInvestor on Jan 17, 2025 9:39pm
I agree very much with this opinion whoever they partner with, I think it would be short sighted to think VM wouldn't be bought out when they 'check all the boxes'. It's nice to have a 35 billion dollar company backing you tho. VM becomes immediately relevant with 20 analysts potentially commenting on the stock. 
Comment by lscfa on Jan 17, 2025 8:12am
GE has to do due diligence on VM's "proprietary streamlined iodine production system"
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.VM

follow v.vm on


Voyageur Pharmaceuticals Deck 2024..

The Watchlist

Voyageur Pharmaceuticals | The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

COMPELLING
VALUE PROPOSITION

  • Only pharmaceutical company in the world that owns long-term supply of barium and iodine
  • Natural barium and iodine resources meet increasingly limited global supply and risk
  • Multi-billion-dollar global market for contrast media
  • Poised to obtain significant market share by offering high-quality, lower-cost products
  • Favorable regulatory pathway allows rapid commercialization
  • Highly experienced team has positioned the company for profitable commercial success

Contact Us

Brent Willis, CEO
Brent@Vpharma.ca

Address:
Suite 1600 Dome Tower, 333 7th Avenue S.W.
Calgary, Alberta
T2P 2Z1